JP2015537190A5 - - Google Patents

Download PDF

Info

Publication number
JP2015537190A5
JP2015537190A5 JP2015533163A JP2015533163A JP2015537190A5 JP 2015537190 A5 JP2015537190 A5 JP 2015537190A5 JP 2015533163 A JP2015533163 A JP 2015533163A JP 2015533163 A JP2015533163 A JP 2015533163A JP 2015537190 A5 JP2015537190 A5 JP 2015537190A5
Authority
JP
Japan
Prior art keywords
cdr
antibody
tnf
variant
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015533163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015537190A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/060480 external-priority patent/WO2014047222A2/en
Publication of JP2015537190A publication Critical patent/JP2015537190A/ja
Publication of JP2015537190A5 publication Critical patent/JP2015537190A5/ja
Pending legal-status Critical Current

Links

JP2015533163A 2012-09-19 2013-09-18 低減された免疫原性を有する抗体を同定するための方法 Pending JP2015537190A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261703170P 2012-09-19 2012-09-19
US61/703,170 2012-09-19
PCT/US2013/060480 WO2014047222A2 (en) 2012-09-19 2013-09-18 Methods for identifying antibodies with reduced immunogenicity

Publications (2)

Publication Number Publication Date
JP2015537190A JP2015537190A (ja) 2015-12-24
JP2015537190A5 true JP2015537190A5 (enExample) 2016-11-04

Family

ID=49304336

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015533163A Pending JP2015537190A (ja) 2012-09-19 2013-09-18 低減された免疫原性を有する抗体を同定するための方法

Country Status (27)

Country Link
US (1) US9279016B2 (enExample)
EP (2) EP2897978B1 (enExample)
JP (1) JP2015537190A (enExample)
KR (1) KR20150056788A (enExample)
CN (1) CN104704000A (enExample)
AU (1) AU2013318147B2 (enExample)
BR (1) BR112015005857A2 (enExample)
CA (1) CA2885422A1 (enExample)
CY (1) CY1118893T1 (enExample)
DK (1) DK2897978T3 (enExample)
ES (1) ES2621285T3 (enExample)
HR (1) HRP20170937T1 (enExample)
HU (1) HUE032569T2 (enExample)
IL (1) IL237833A0 (enExample)
IN (1) IN2015DN01967A (enExample)
LT (1) LT2897978T (enExample)
MX (1) MX2015003541A (enExample)
NZ (1) NZ705606A (enExample)
PL (1) PL2897978T3 (enExample)
PT (1) PT2897978T (enExample)
RS (1) RS56093B1 (enExample)
RU (1) RU2648141C2 (enExample)
SG (1) SG11201502094TA (enExample)
SI (1) SI2897978T1 (enExample)
SM (1) SMT201700255T1 (enExample)
TW (1) TWI519646B (enExample)
WO (1) WO2014047222A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位,含此表位的多抗原肽及应用
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
JP7473339B2 (ja) * 2017-03-07 2024-04-23 エフ. ホフマン-ラ ロシュ アーゲー 代替の抗原特異的抗体変異体を発見するための方法
TW202039554A (zh) * 2018-12-19 2020-11-01 瑞士商諾華公司 抗TNF-α抗體
CN114401988A (zh) * 2019-07-09 2022-04-26 国家生物技术研究所公司 具有降低的免疫原性的抗体
WO2021064009A1 (en) 2019-09-30 2021-04-08 Scirhom Gmbh Protein binders to irhom2 epitopes
FR3104582A1 (fr) * 2019-12-17 2021-06-18 Commissariat A L'energie Atomique Et Aux Energies Alternatives Variants de l’adalimumab au potentiel immunogène réduit
CN113125714B (zh) * 2019-12-31 2023-06-16 科美博阳诊断技术(上海)有限公司 一种人类免疫缺陷病毒抗体检测试剂盒及其应用
WO2021147642A1 (en) * 2020-01-20 2021-07-29 Bio-Thera Solutions, Ltd. Methods, models and systems related to antibody immunogenicity
KR102568430B1 (ko) * 2020-11-16 2023-08-24 바디텍메드(주) 항 약물 항체의 신속 검출 방법
MX2023010055A (es) 2021-03-01 2023-11-17 Scirhom Gmbh Anticuerpos humanizados contra irhom2.
US20240174744A1 (en) 2021-03-29 2024-05-30 Scirhom Gmbh Methods of treatment using protein binders to irhom2 epitopes
WO2022214664A1 (en) 2021-04-09 2022-10-13 Philogen S.P.A. Improved interferon-gamma mutant
WO2024023246A1 (en) 2022-07-28 2024-02-01 Philogen S.P.A. Antibody binding to pd1
CN119998325A (zh) 2022-08-08 2025-05-13 Atb治疗公司 抗CD79b的人源化抗体
WO2025180665A1 (en) 2024-02-28 2025-09-04 Evotec International Gmbh Antibodies binding to cd2, and multifunctional molecules comprising such antibodies
WO2025242726A1 (en) 2024-05-21 2025-11-27 Onconick Ltd. Antibody binding to FGFR1 and conjugates comprising the same
WO2026087776A1 (en) * 2024-10-25 2026-04-30 Kyron.bio SAS Therapeutic molecules that bind tnf alpha

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
DE3687170T2 (de) 1985-01-25 1993-04-01 Kitasato Inst Antitumorale antibiotika und deren herstellung.
US5264357A (en) 1985-05-24 1993-11-23 Genentech, Inc. Nucleic acids vectors and cells for the synthesis of membrane anchor fusion polypeptides
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
ATE239041T1 (de) * 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6787308B2 (en) 1998-07-30 2004-09-07 Solexa Ltd. Arrayed biomolecules and their use in sequencing
AR021833A1 (es) 1998-09-30 2002-08-07 Applied Research Systems Metodos de amplificacion y secuenciacion de acido nucleico
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
US7211390B2 (en) 1999-09-16 2007-05-01 454 Life Sciences Corporation Method of sequencing a nucleic acid
WO2001023610A2 (en) 1999-09-29 2001-04-05 Solexa Ltd. Polynucleotide sequencing
US6686168B1 (en) 1999-11-04 2004-02-03 Zymogenetics, Inc. Cell surface display of proteins by recombinant host cells
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6897023B2 (en) 2000-09-27 2005-05-24 The Molecular Sciences Institute, Inc. Method for determining relative abundance of nucleic acid sequences
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6956114B2 (en) 2001-10-30 2005-10-18 '454 Corporation Sulfurylase-luciferase fusion proteins and thermostable sulfurylase
US7057026B2 (en) 2001-12-04 2006-06-06 Solexa Limited Labelled nucleotides
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040115814A1 (en) 2002-09-30 2004-06-17 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
TWI439284B (zh) * 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療TNFα相關失調症之多重可變劑量療法
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
JP2009515878A (ja) 2005-11-12 2009-04-16 イーライ リリー アンド カンパニー 抗egfr抗体
WO2009032128A1 (en) * 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab
WO2009059235A2 (en) 2007-11-01 2009-05-07 Facet Biotech Corporation Immunoglobulin display vectors
RU2595379C2 (ru) * 2009-04-16 2016-08-27 АббВай Биотерапеутикс Инк. АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
NZ602220A (en) * 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
BR112013002444A2 (pt) * 2010-08-13 2016-05-24 Roche Glycart Ag anticorpo, polinucleotídeo e polipeotídeo isolados, composição, vetor, cécula hospedeira, conjulgado de anticorpo, formulação farmacêutica, uso do anticorpo, métodos para produzir um anticorpo, tratar um indivíduo, induzir a lise celular de uma célula tumorosa e diagnosticar uma doença em um indivíduo
CN103534268B (zh) * 2010-10-20 2016-05-18 牛津生物疗法有限公司 抗体

Similar Documents

Publication Publication Date Title
RU2015111671A (ru) Способы идентификации антител с пониженной иммуногенностью
AU2016223095B2 (en) Antibodies to tau and uses thereof
TW201833141A (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
HRP20191697T1 (hr) Vezujuće molekule za bcma i cd3
CA2989637C (en) Cys80 conjugated immunoglobulins
JP2018510868A (ja) 二重特異性抗体を精製する方法
KR20130010123A (ko) TNF-α 결합 단백질
RU2012131671A (ru) Способ полипептидной модификации для очистки полипептидных мультимеров
JP2023509390A5 (enExample)
JP2009509538A5 (enExample)
CN113912731A (zh) 一种抗fgl1抗体及其应用
JP2018148915A (ja) 抗vasa抗体、ならびにその産生法および使用法
JP2023549555A5 (enExample)
JP2022512672A (ja) アントラサイクリンを含む結合タンパク質-毒素融合体、および免疫腫瘍学的適用におけるその使用
KR20220030934A (ko) 항-gal9 면역-억제 결합 분자
EP3024849A2 (en) Novel antibodies for the diagnosis and treatment of rheumatoid arthritis
JP2020505465A5 (enExample)
TW202045132A (zh) 生成包含有兩種或更多種抗體的組成物之技術
CN104558172A (zh) 一种针对β淀粉样蛋白的单域重链纳米抗体及其应用
WO2024161375A1 (en) Human anti-pd-l2 antibody and its uses thereof
AU2020322765A1 (en) Bispecific antibody
CN117924481A (zh) 抗犬il-31单克隆抗体及其应用
CN118085082A (zh) 抗猫TNF-α单克隆抗体及其应用
JP2020531041A (ja) ポリペプチドとポリペプチドに結合される抗体
US20130109586A1 (en) Generation of antibodies to an epitope of interest that contains a phosphomimetic amino acid